GeoVax Labs (GOVX) Q3 2026 earnings summary

Executive summary

• Clinical-stage vaccine and immunotherapy development is focused on GEO-MVA for mpox/smallpox and Gedeptin for head and neck cancer; both trial plans depend on financing.

• Cash and cash equivalents were $2.15M at September 30, 2026; available resources, including access to a new credit facility, were expected to fund operations into December 2026, with substantial doubt about going concern.

Financial highlights

• Q3 2026 operating expenses were $4.17M vs. $6.37M YoY; net loss was $4.16M vs. $6.32M.

• 9M 2026 operating expenses were $13.89M vs. $19.69M; net loss was $13.84M vs. $17.05M.

• No government-contract revenue was recorded in 9M 2026 vs. $2.49M in 9M 2025, related to the BARDA contract terminated in April 2025.

• Q3 2026 R&D was $2.82M, down 44.1% YoY; G&A was $1.35M, up 1.9% YoY.

Outlook and guidance

• GEO-MVA Phase 3 initiation in Europe is targeted for late 2026, subject to financing, final protocol and regulatory alignment.

• Gedeptin Phase 2, with an immune checkpoint inhibitor and first-line treatment, is targeted for H2 2027, subject to financing.

• R&D and G&A spending are expected to rise as clinical programs advance and potential commercialization preparations expand.

• Additional capital is needed; planned sources include equity or debt, government grants/contracts and strategic partnerships, with no assurance of availability on favorable terms or at all.